Related Experiment Video
Updated: Feb 13, 2026

Myeloid Innate Signaling Pathway Regulation by MALT1 Paracaspase Activity
Published on: January 7, 2019
Decoy receptor 3 alleviates hepatic fibrosis through suppressing inflammation activated by NF-κB signaling pathway
Zhenjing Jin1, Siqi Liu1, Qian Zhan1
1The Second Clinical Hospital, Jilin University, Changchun, China
Background:
Hepatic fibrosis is a reversible pathological process. Inflammatory responses are the prevailing reactions during hepatic fibrosis. Decoy receptor 3 (DcR3) has been reported to have an anti-inflammatory effect.
Objectives:
The aim of the study was to investigate the preventive effects of DcR3 on hepatic fibrosis.
Material And Methods:
Hepatic fibrosis was induced in rats by administering intraperitoneally (ip.) 1% dimethylnitrosamine (DMN). DcR3 plasmid was delivered into rats by intravenous injection. After 4 weeks, the expression of DcR3, TNF-like molecule 1A (TL1A) and α-SMA of the liver tissue were checked. The levels of inflammatory cytokines such as TNF-α, IL-6 and IL-1β were detected using western blotting and quantitative real-time reverse transcription-polymerase chain reaction (qRT-PCR). Masson's trichrome staining for histopathological changes of the liver tissue was observed. Finally, the activity of NF-κB in the liver was examined by enzyme-linked immunosorbent assay (ELISA).
Results:
A higher expression of DcR3 was observed in rats treated with DcR3 (p < 0.05). Histological results showed that DcR3 significantly attenuated pathology in hepatic fibrosis rats. Consistently, mRNA and protein levels of α-SMA, TL1A, TNF-α, IL-6, and IL-1β were repressed in the liver tissue after treatment with DcR3 (p < 0.05). Moreover, DcR3 also inhibited the activation of NF-κB in the liver tissue (p < 0.05).
Conclusions:
This study demonstrated that DcR3 attenuated liver injury and inflammatory responses in rats with hepatic fibrosis. We suggest DcR3 may be a prophylactic and promising therapeutic agent in the treatment of hepatic fibrosis.
Insights
Decoy receptor 3 (DcR3) effectively reduced liver injury and inflammation in rats with hepatic fibrosis. This suggests DcR3 shows promise as a potential prophylactic and therapeutic agent for treating liver fibrosis.
Area of Science:
- Hepatology
- Immunology
- Biomedical Research
Background:
- Hepatic fibrosis is a pathological process characterized by inflammation.
- Decoy receptor 3 (DcR3) exhibits anti-inflammatory properties.
Purpose of the Study:
- To investigate the potential preventive effects of DcR3 on hepatic fibrosis.
- To evaluate DcR3 as a therapeutic agent for liver fibrosis.
Main Methods:
- Hepatic fibrosis induced in rats using dimethylnitrosamine (DMN).
- DcR3 plasmid delivered via intravenous injection.
- Analysis of liver tissue for DcR3, TL1A, α-SMA, inflammatory cytokines (TNF-α, IL-6, IL-1β), and NF-κB activation.
Main Results:
- DcR3 treatment significantly increased DcR3 expression in rat livers.
- DcR3 administration attenuated liver pathology and reduced α-SMA, TL1A, TNF-α, IL-6, and IL-1β levels.
- DcR3 inhibited NF-κB activation in the liver tissue.
Conclusions:
- DcR3 demonstrates efficacy in attenuating liver injury and inflammatory responses in a rat model of hepatic fibrosis.
- DcR3 is a promising prophylactic and therapeutic candidate for hepatic fibrosis treatment.
More Related Videos
06:09Author Spotlight: Advancing Hepatic Fibrosis Diagnosis Using Magnetic Resonance Elastography and AI
Published on: July 21, 2023
06:38An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
Published on: September 12, 2019
Related Concept Videos
NF-κB-dependent Signaling Pathway
NF-κB-dependent Signaling Mechanism
The...
Insulin: The Receptor and Signaling Pathways
Notch Signaling Pathway
The Notch gene came into the limelight in 1914 after the discovery that its mutation in Drosophila melanogaster leads to a serrated (or "notched") wing margin phenotype. It was not...
Hedgehog Signaling Pathway
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Non-Canonical Wnt Signaling Pathways